123rf.com/IculigAgomabAgomab raises US$89m in Series DAnother strong financing round for Belgian Agomab NV. Sanofi is joining the band wagon of targeting the TGFbeta receptor. more ➔
Rentschler Biopharma SEBiomanufacturingRentschler with double-digit investment in...Rentschler Biopharma announces largest single investment in the higher double-digit range at its headquarters in Germany for construction of a new buffer media facility in Laupheim. more ➔
Roche, Herzog&De MeuronAlzheimer’s DiseaseRoche leaves Alzheimer partnership with UC...Roche drops a third Alzheimer’s candidate this year, leaving a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease. more ➔
NucleraNuclera Secures US$75m to Advance Protein...Biotech firm Nuclera raises $75M to expand its cutting-edge protein discovery system, speeding up breakthroughs in labs worldwide. more ➔
Image by freepikGene therapyPurespring bags £80m to transform kidney...Purespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this … more ➔
World Health SummitWHS 2024WHO: One billion US$ for global healthA total of US$1bn was pledged to the WHO at this year’s World Health Summit in Berlin for the fight against Mpox, Marburg virus and the consequences of climate change. more ➔
Ikerian AGAISwiss Ikerian AG partner with Sanoptis Inc...Swiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside … more ➔
Molcure IncPartnershipAntibody developer Yumab partners with Jap...German antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery. more ➔
Stijnstijl fotografieVCForbion raises more than €2bn for two ne...Dutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m. more ➔
H.Lundbeck A/SM&ALundbeck to take over Longboard Pharma in...Lundbeck A/S is set to take over all shares of neurology specialist Longboard Pharmaceuticals Inc worth US$2.6bn to strengthen its pipeline with the Phase III 5-hydroxythyprytamaine 2C receptor super-agonist … more ➔
123rf.com/Iculig
Rentschler Biopharma SE
Roche, Herzog&De Meuron
Image by freepik
World Health Summit
Ikerian AG
Molcure Inc
Stijnstijl fotografie
H.Lundbeck A/S